Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:SLS News 18 October 2025 - 2 January 2026

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences shares surged on heavy volume to $2.64 after the company presented updated Phase 2 data for SLS009 in relapsed/refractory AML at ASH 2025. The study showed a 46% overall response rate among 35 patients, with no dose-limiting toxicities reported. Final analysis of the Phase 3 REGAL trial for galinpepimut-S is expected by year-end.
23 December 2025
·
Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (NASDAQ: SLS) stock has surged roughly 100% year-to-date, closing around $2.14 on Oct. 17, 2025 ts2.tech ts2.tech (versus a 52-week low of $0.77). In after-hours trading on Oct. 17 it spiked another +38%, briefly touching a new 52-week high ts2.tech. Big investors are piling in: BlackRock disclosed a 5.4% stake (~5.7M shares) in SLS on Oct. 18 ts2.tech, and other funds like Vanguard and Marshall Wace added millions of shares in Q2 quiverquant.com. On the drug-development front, Sellas’s lead AML immunotherapy (galinpepimut‑S, “GPS”) is in a Phase 3 AML trial (REGAL), which recently passed an interim safety review
20 October 2025
··
Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Stock Price and Performance As of mid-October 2025, Sellas Life Sciences (NASDAQ:SLS) trades around $2.10–2.20. This is near the top of its 52-week range ($0.77 low) and about twice its price at the start of 2025 stockanalysis.com marketbeat.com. Trading volume and volatility have picked up – for instance, on Oct. 14 a massive spike in call-option activity (761% above average) coincided with bullish sentiment marketbeat.com. The stock’s YTD gain (~100%) far outpaces many small-cap biotechs. Technical platforms note SLS is in “uptrend” territory: the stock is well above its 20-day EMA ($1.89) and 50-day EMA ($1.81) tipranks.com, which TipRanks flags
18 October 2025
··
BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

Key Facts – October 18, 2025 Stock Performance: SLS on a Tear in 2025 SELLAS Life Sciences’ stock has been on a remarkable run this year. Shares have effectively doubled in 2025, and the momentum accelerated in mid-October. On Friday Oct. 17, SLS closed at $2.14, up roughly 100% year-to-datefinbold.com. In fact, during that day’s session the stock touched a 52-week high of $2.27 (more than 3× its 52-week low of $0.77)marketbeat.com. Trading activity exploded as well – volume spiked to several times the usual level (over 6.7 million shares vs ~2.2M average) amid a flurry of speculative buying. Options
18 October 2025

Stock Market Today

Idox share price stuck below 71.5p bid as Long Path says backing nears control

Idox share price stuck below 71.5p bid as Long Path says backing nears control

8 February 2026
Long Path Partners said it has aggregate support for about 49.26% of Idox shares for its 71.5p-per-share cash offer. Idox shares closed Friday at 71.0p, about 0.7% below the offer price. Valid acceptances stood at 19.12% as of Feb. 5, with the offer open until March 16. The deal requires more than 50% of voting rights to go unconditional.
BAE Systems share price: Buyback update and Launchpad incubator set up Feb 18 results

BAE Systems share price: Buyback update and Launchpad incubator set up Feb 18 results

8 February 2026
BAE Systems shares closed up 1.2% at 1,879 pence on Friday, with 5.6 million shares traded. The company disclosed buying back 115,039 shares for cancellation at a volume-weighted average price of 1,860.32 pence. Over 1,200 BAE workers in northwest England are striking over pay until at least Feb. 20. Full-year results are due Feb. 18.
Barclays share price jumps into earnings week: what to watch before Tuesday’s results

Barclays share price jumps into earnings week: what to watch before Tuesday’s results

8 February 2026
Barclays shares closed up 2.71% at 479.1 pence on Friday, ahead of full-year results and a targets update due Tuesday. Barclays and NatWest have both submitted offers for Evelyn Partners, with a deal announcement possible this week, according to Reuters. Mary Francis will retire from the Barclays board in May. Investors are watching for signals on costs, credit quality, and capital returns.
Rolls-Royce share price ends week higher on buyback update as RR.L eyes turn to results

Rolls-Royce share price ends week higher on buyback update as RR.L eyes turn to results

8 February 2026
Rolls-Royce Holdings shares closed at 1,229p on Friday, up 1.78%, as the FTSE 100 gained 0.59%. The company reported buying 742,570 shares on Feb. 5 as part of its £200 million buyback, bringing total repurchases to 12.66 million shares. Rolls-Royce will attend the World Defense Show in Riyadh, noting over 80% of its Saudi workforce are nationals.
Go toTop